TopGum Moves into Pharmaceutical Market with US Manufacturing Acquisition
Published: 31 Mar 2026
Author: Precedence Research
TopGum Industries, a global leader in gummy-based dietary supplements, has signed a binding letter of intent to acquire US-based operations specializing in the production of pharmaceutical and supplement gummies. This strategic move marks the company’s entry into the pharmaceutical sector, expanding its capabilities beyond nutraceutical products.
The acquisition includes operations recognized as the first globally to establish manufacturing capabilities for pharmaceutical-grade gummies containing active pharmaceutical ingredients. This positions TopGum at the forefront of an emerging dosage format that combines patient convenience with clinical efficacy.
Advancing Pharmaceutical-Grade Gummy Manufacturing
The seller is a prominent US organization involved in generic pharmaceuticals and contract development and manufacturing services. It maintains strong relationships with major retail chains across the United States, providing TopGum with valuable commercial access and distribution channels.
As part of the transaction, TopGum will acquire a fully operational manufacturing facility in the US. The site includes active production lines, a laboratory trials line, and infrastructure designed for future capacity expansion. The facility already complies with US regulatory requirements and is expected to meet Australian regulatory standards following a short certification process, enabling further international expansion.
Acquisition of FDA-Compliant Manufacturing Facility
The total consideration for the deal includes a cash payment of $12 million at closing, along with the issuance of shares valued at $13 million. Additional contingent consideration of up to $12 million may be issued in shares, subject to the achievement of predefined sales targets.
According to Towards FnB, the U.S. nutraceutical gummies market size was valued at 7.72 in 2025 and is projected to witness robust growth, increasing from USD 8.85 billion in 2026 to approximately USD 30.87 billion by 2035, at a CAGR of 14.87% during the forecast period. The market growth driven by increasing consumer preference for convenient and palatable supplement formats. One of the primary drivers of this market is the growing demand for patient-friendly dosage forms, particularly among pediatric and geriatric populations, where traditional tablets and capsules often face compliance challenges.
In addition to the acquisition, both parties have agreed to establish a long-term strategic collaboration focused on the commercialization of gummy-based dietary supplements and pharmaceutical products. The agreement also includes plans for the seller to nominate a representative to join TopGum’s board of directors.
The acquired operations bring with them a pipeline of pharmaceutical gummy products, with initial launches anticipated to begin in 2026. Among these is a high-profile development project involving a gummy version of an existing drug, targeting a market estimated at $1.5 billion annually. This product is being fully funded by a pharmaceutical partner and is expected to launch in 2027.
The development pipeline associated with the acquisition is estimated to generate approximately $60 million over the next two to three years. Company leadership emphasized that this transaction represents a key milestone, strengthening TopGum’s position for sustained global growth and innovation in advanced delivery formats.